MS-ResearchBiomarkerS
Investigating the Longitudinal Relationships Between Visual Pathway Injury, Radiological and Blood Biomarkers in Multiple Sclerosis and Related Disorders
Cedars-Sinai Medical Center
1,000 participants
Nov 11, 2021
OBSERVATIONAL
Conditions
Summary
This study is being conducted to investigate risk factors for disability progression in Multiple Sclerosis and related disorders (MSRD). The primary goal is to assess whether combining information from visual assessment, blood markers, as well as historical and ongoing longitudinal MRIs of the brain, orbit (the part of the skull where eyes are located), and/or spinal cord can predict changes in quantitative disability measures related to MSRD and neurological disease.
Eligibility
Inclusion Criteria8
- Subjects who meet any one of the following diagnostic criteria:
- Diagnosis of MS, CIS,or RIS based on the 2017 revised McDonald criteria.
- Diagnosis of NMOSD based on the 2015 revised NMOSD consensus diagnostic criteria.
- Diagnosis of myelin oligodendrocyte glycoprotein (MOG)-related encephalomyelitis, optic neuritis, or other associated disease.
- Diagnosis of neurological disorders other than MSRD.
- Healthy volunteer.
- Age ≥18.
- Able to give informed consent.
Exclusion Criteria3
- Patients will be excluded from the MRI portions of the study if they have a contraindication to MRI(metallic implantsor foreign bodies, claustrophobia, MRI-incompatible pacemakers, MRI- incompatible prosthetic heart valves).
- Patients will be excluded from the MRI portions of the study if they are pregnant, but their demographic, clinical information,and disability measures may still be captured under the study.
- Patients will be excluded from the visual assessment portions of the study if they have had any recent ocular surgery (within the past two months), refractive errors of greater than or equal to ±6 diopters or other eye diseases that may affect or confound OCT/OCTA measurements (ex., age-related macular degeneration, advanced geographic atrophy, diabetic retinopathy, glaucoma).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05204459